Pharmaceutical

NICE recommends Pfizer’s Ritlecitinib for alopecia areata treatment

The UK NICE has recommended Pfizer's Ritlecitinib as a new treatment option for individuals suffering from alopecia areata.

Feb 24, 2024 - 18:00
NICE recommends Pfizer’s Ritlecitinib for alopecia areata treatment
The UK NICE has recommended Pfizer's Ritlecitinib as a new treatment option for individuals suffering from alopecia areata.
Read the original article

Tags:

Previous Article

Moderna reports net loss of $4.7bn for full year 2023

Next Article

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: The biotech scorecard for the second quarter: 24 stock-moving events to watch

STAT+: The biotech scorecard for the second quarter: 24...

Apr 3, 2023

Diffusion Pharma’s stockholders support merger with EIP Pharma

Diffusion Pharma’s stockholders support merger with EIP...

Aug 16, 2023

STAT+: Biogen Alzheimer’s drug launch off to slow start

STAT+: Biogen Alzheimer’s drug launch off to slow start

Feb 13, 2024